AI Ethics in Pharma & Life Sciences: A Market-Oriented Approach? Dec 4th, 5-7pm

AI Ethics in Pharma & Life Sciences: A Market-Oriented Approach?

When: December 4th, 17:00-19:00

Where: Digital Society Initiative, Rämistrasse 69, Zurich

Organizers: DSI and MQ Learning Academy

Registration

Description

In today’s rapidly evolving digital landscape, AI and other emerging technologies are transforming industries, including healthcare and pharma, by offering innovative capabilities and enhanced efficiency. However, the rise of AI brings with it new ethical challenges beyond traditional concerns of security and data protection. 

In this session, we will explore the importance of AI ethics within the pharma and life sciences sectors, focusing on practical strategies to mitigate risks while ensuring AI-driven innovation. We’ll examine how a market-oriented approach can be combined with regulatory frameworks to address these concerns responsibly. Additionally, we’ll present key findings from an Innosuisse-funded study, conducted in collaboration with the University of Zurich and MQ Academy, on AI ethics in pharma and life sciences.

Agenda:

5:00 – 5:10 Welcome

5:10-5:40 Innocheque study results Ethical Decision Making Intelligence for Healthcare by Deepak Bansal (Founder, MQ Learning Academy), Michele Loi (Independent Consultant) (via Zoom), and Christian H. Hoffmann, will present the findings of an Innosuisse-funded research study on the critical role of AI ethics in healthcare. The presentation will highlight the study’s insights into the need for ethical frameworks in AI applications within healthcare and the essential role that education can play in fostering ethical decision making

5:40-5:50 Q&A

5:50-6:10 Implementing Ethical AI at Roche by Dr. Katrina Bramstedt (Global Head of Bioethics) will provide an overview of the work her team is doing to implement Ethical AI at Roche. She will discuss the significance of Ethical AI for the pharmaceutical industry, particularly for Roche, and explain how it differs from Responsible AI. Additionally, Dr. Bramstedt will outline the specific practices and initiatives Roche is undertaking to ensure the integration of Ethical AI principles.

6:10-6:20 Q&A

6:20-6:40 Turning AI Ethics into Action: The Challenges of Responsible AI (RAI) for consultancies and their clients by Dr. Eleonora Viganò (University of Zurich and University of Applied Sciences of the Grisons), will share findings from the Innossuisse IB Databooster project on the implementation of RAI in Swiss companies. Drawing on insights from 11 interviews with consultancies, their clients, and RAI experts and a workshop in partnership with six Swiss companies, she will offer an overview of the main pains and gains companies experience with RAI implementation. She will also outline the initial solutions proposed to help organizations overcome these challenges. The presentation will focus on the gap between the numerous high-level RAI frameworks available and the difficulties companies face in applying these frameworks within their workflows and adapting them to their specific industries, sectors, and departments.

6:40-6:50 Q&A

6:50-7:15 Discussion

Why Attend?

This event is an excellent opportunity for professionals in the pharmaceutical industry, AI specialists, ethicists, and regulatory bodies to gain a deeper understanding of how AI ethics can be managed within the unique context of pharma. Whether you’re looking to enhance your company’s AI governance strategy or simply learn more about the ethical implications of AI in this sector, this event will offer valuable insights and practical takeaways.